Dover Corporation (NYSE: DOV), a diversified global manufacturer with over $8 billion in annual revenue, announced the launch of the RevolveSD Series on July 15, 2026 through its CPC Biotech subsidiary, part of Dover's Pumps & Process Solutions segment. The RevolveSD is a one-inch flow path, single-use sterile disconnect for biopharmaceutical processing that enables sterile tubing disconnection in seconds without clamps, sealers, or special equipment. The launch extends CPC Biotech's AseptiQuik(R) connector heritage into larger-scale, higher-flow bioprocessing workflows where existing sterile disconnect options have historically fallen short.

Sterile Disconnection Has Been a Bottleneck in Large-Scale Bioprocessing

Single-use bioprocessing systems have largely displaced stainless steel equipment in biopharmaceutical manufacturing because they eliminate cleaning validation, reduce contamination risk, and compress changeover time between batches. Sterile connectors and disconnectors sit at every fluid transfer point in those systems, and their performance directly affects process integrity and throughput. At larger flow rates--cell culture, harvest, filtration, and fill-finish operations that use one-inch or wider tubing--sterile disconnection has required either complex clamping hardware or heat sealers, both of which add steps, equipment, and failure points to the process. RevolveSD addresses that gap directly. Its dual-valve, non-spill technology minimizes residual fluid on the external valve face after disconnection, and its one-inch flow path supports smooth bidirectional flow without turbulence or restriction. As a true one-time disconnect, the product also prevents unintended reconnection--a critical safeguard against sterility breaches that could compromise a batch worth millions of dollars.

Material Choice Targets Antibody Drug Conjugate and Harsh Chemical Applications

CPC Biotech manufactured RevolveSD from polyphenylsulfone (PPSU), a high-performance thermoplastic that withstands harsh chemicals including the cytotoxic linker-payload reagents used in antibody drug conjugate manufacturing. ADC production has grown rapidly as the modality has moved from niche oncology applications into broader clinical pipelines, and the harsh chemical compatibility requirement has historically limited the field of viable single-use components for those workflows. By specifying PPSU and designing a metal-free construction, CPC Biotech eliminates corrosion risks in the flow path and positions RevolveSD for ADC manufacturing environments that conventional wetted materials cannot serve. That targeted application focus builds on CPC Biotech's existing specification wins across biologics, vaccines, cell therapy, and gene therapy manufacturing.

Single-Use Biopharma Drives the Pumps & Process Solutions Growth Story

RevolveSD lands at a moment of sustained commercial momentum for Dover's Pumps & Process Solutions segment. The segment generated $537.8 million in Q1 2026 revenue, up 9% year over year, with segment earnings rising 12% to $169.5 million. Dover's 10-Q specifically identifies robust demand for single-use biopharma components as a key driver of organic growth, a trend management expects to continue through 2026. Dover CEO Richard Tobin highlighted single-use biopharma components as one of the segment's most compelling growth vectors alongside precision measurement and industrial pumps. The RevolveSD launch directly feeds that pipeline--it targets the large-scale manufacturing phase where batch volumes and processing times are highest, meaning each specification win with a major biologics manufacturer creates a recurring consumables revenue stream that scales with production output.

Strategic Investment Summary

• Product Launch: Dover Corporation (NYSE: DOV) launched the RevolveSD Series on July 15, 2026, through its CPC Biotech subsidiary--a one-inch, single-use sterile disconnect for biopharmaceutical processing that completes sterile tubing disconnections in seconds without clamps or sealers.
• Technical Differentiation: RevolveSD's dual-valve, non-spill design minimizes residual fluid after disconnection, its one-inch flow path supports smooth bidirectional flow, and its true single-use architecture prevents unintended reconnection to protect process sterility.
• Material Advantage: Polyphenylsulfone (PPSU) construction and metal-free design give RevolveSD compatibility with harsh chemicals used in antibody drug conjugate manufacturing--an application where conventional single-use materials face significant limitations.
• Segment Momentum: Dover's Pumps & Process Solutions segment delivered $537.8 million in Q1 2026 revenue, up 9% year over year, with single-use biopharma components identified in the 10-Q as a primary driver of organic growth.
• Recurring Revenue Model: Each RevolveSD specification win at a biologics manufacturing site creates a recurring consumables revenue stream that scales with production output, as single-use disconnectors require replacement with every batch.
• Portfolio Context: RevolveSD extends CPC Biotech's AseptiQuik(R) heritage into larger-scale workflows, complementing Dover's broader single-use biopharma connector portfolio that also serves liquid cooling in high-performance computing and data center applications.

Find out more about the latest corporate developments and financial reports at the Dover Corporation investor portal.

The post Dover’s CPC Biotech Launches RevolveSD(TM) Series, Bringing One-Inch Sterile Disconnect to Large-Scale Bioprocessing appeared first on PRISM MarketView.

COMTEX_489012520/2927/2026-07-19T07:30:38